A group of outside experts working inside CDRH has pinpointed significant variability in how FDA approves new clinical trials and is proposing new agency metrics to improve the investigational device exemption process.
Efforts by participants in the device center’s entrepreneurs-in-residence program are still under way, but FDA officials have so far been...